Darovasertib Combination Therapy Significantly Improves Survival Rates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Source: Newsfilter
- Clinical Trial Results: At the 2026 ASCO Annual Meeting, IDEAYA presented data showing that the darovasertib and crizotinib combination therapy achieved a median progression-free survival (PFS) of 6.9 months compared to 3.1 months in the control group, indicating its potential as a new therapeutic standard for HLA*A2:01 negative metastatic uveal melanoma.
- Efficacy Metrics Improvement: The combination therapy demonstrated an overall response rate (ORR) of 37.1%, significantly higher than the 5.8% in the control group, suggesting a substantial therapeutic effect that could alter current treatment protocols.
- Good Safety Profile: The safety profile of the combination therapy was consistent with prior results, with treatment-related serious adverse events (TR-SAE) occurring at a rate of 9.2%, lower than the 25.0% in the control group, indicating good tolerability and low discontinuation rates.
- Regulatory Submission Progress: IDEAYA is in the process of submitting a New Drug Application (NDA), expected to be completed in the second half of 2026, which, if approved, will provide new treatment options in this field and further enhance the company's leadership in precision medicine.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IDYA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IDYA
Wall Street analysts forecast IDYA stock price to rise
15 Analyst Rating
13 Buy
2 Hold
0 Sell
Strong Buy
Current: 27.870
Low
30.00
Averages
49.86
High
79.00
Current: 27.870
Low
30.00
Averages
49.86
High
79.00
About IDYA
IDEAYA Biosciences, Inc. is a medicine oncology company. The Company is engaged in the discovery, development, and commercialization of transformative therapies for cancer. Its product candidates focus on synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications. Its product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE161 (PARG), IDE275 (Werner Helicase) and IDE705 (Pol Theta Helicase). Darovasertib is a clinical stage, potent and selective small molecule inhibitor of PKC, a protein kinase that functions downstream of the GTPases GNAQ and GNA11. IDE397 is an oral small molecule inhibitor of methionine adenosyl transferase 2a (MAT2A). IDE161 is an oral small molecule poly (ADP-ribose) glycohydrolase (PARG) inhibitor. IDE275 is an oral small molecule inhibitor of the helicase domain of the Werner protein (WRN), a RecQ enzyme involved in the maintenance of genome integrity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IDEAYA Enters Clinical Collaboration with Roche for IDE892 Evaluation
- Clinical Collaboration Initiated: IDEAYA has entered into a clinical collaboration with Roche to evaluate its potential best-in-class PRMT5 inhibitor, IDE892, in combination with Roche's RG6505 for MTAP-deleted pancreatic ductal adenocarcinoma patients, demonstrating a strong response to unmet medical needs.
- Trial Design and Implementation: IDEAYA will sponsor the clinical trial while Roche will supply RG6505, with joint governance ensuring scientific rigor and efficacy of the study, thereby advancing the development of new therapies.
- Market Potential Assessment: MTAP deletion occurs in up to 40% of pancreatic ductal adenocarcinoma cases, with nearly all MTAP-deleted cases harboring RAS mutations, indicating that combination therapy may provide new targeted treatment options for these patients, filling a significant market gap.
- Future Development Plans: The collaboration may also evaluate a triplet therapy involving IDE892, RG6505, and IDE397 upon joint approval, further expanding IDEAYA's drug combination strategy for MTAP-deletion, enhancing its competitiveness in the precision medicine field.
See More
IDEAYA Partners with Roche for Clinical Trial of IDE892
- Clinical Collaboration Initiated: IDEAYA has entered into a clinical collaboration with Roche to evaluate the efficacy and safety of its potential best-in-class PRMT5 inhibitor, IDE892, in combination with Roche's RG6505 for pancreatic ductal adenocarcinoma (PDAC), marking a significant advancement in the company's precision medicine strategy.
- Addressing Market Needs: With MTAP deletions occurring in up to 40% of PDAC cases and almost no approved targeted treatment options available, this collaboration aims to fill a critical gap in the market, potentially leading to the development of new therapeutic options for patients.
- Strategic R&D Integration: IDE892 has demonstrated robust monotherapy regressions in preclinical models with MTAP deletions, and the clinical trial combining it with RG6505 will provide crucial data to support IDEAYA's MTAP deletion drug portfolio, enhancing the competitiveness of its pipeline.
- Future Development Potential: The collaboration also allows for the evaluation of a triplet therapy involving IDE892, RG6505, and IDE397, which, if approved, could open new avenues for IDEAYA in precision oncology, significantly boosting its market position.
See More
IDEAYA and Roche Collaborate on New Cancer Therapy Evaluation
- Joint Clinical Trial: IDEAYA Bioscience and Roche have agreed to evaluate a combination therapy of IDE892 and RG6505, targeting pancreatic cancer patients with MTAP deletion, which occurs in up to 40% of cases, indicating potential treatment hope.
- Drug Mechanism Analysis: IDE892, an MTA-cooperative PRMT5 inhibitor, combined with Roche's pan-RAS inhibitor RG6505, may offer deeper and more durable responses for patients currently lacking approved targeted treatment options.
- Trial Sponsorship: IDEAYA will sponsor this clinical trial, further advancing research on RAS-mutant pancreatic cancer with MTAP deletion, aiming to fill treatment gaps and improve patient survival rates.
- Triple Combination Evaluation: The collaboration will also assess a triplet combination of IDE892, RG6505, and IDE397, the latter being IDEAYA's phase 2 MAT2A inhibitor, potentially providing more treatment options for patients.
See More
IDEAYA and Servier Present OptimUM-02 Trial Data for Darovasertib at ASCO 2026
- Clinical Trial Progress: At the 2026 ASCO Annual Meeting, IDEAYA and Servier presented data on the combination of darovasertib and crizotinib for HLA*A2:01 negative metastatic uveal melanoma, demonstrating significant efficacy compared to existing treatments, potentially establishing a new therapeutic standard.
- Patient Recruitment: The OptimUM-02 trial enrolled 313 patients, randomized 2:1 to compare the darovasertib combination with investigator's choice therapy, highlighting the combination's potential in patients with no effective treatment options.
- FDA Review Progress: IDEAYA received FDA agreement in April 2026 to initiate the drug application review for darovasertib, with expectations to complete the filing in the second half of 2026, aiming to expedite the availability of new therapies to meet patient needs.
- Commitment to R&D Investment: Servier achieved €6.9 billion in revenue for the 2024/25 fiscal year and plans to invest nearly 20% of its brand sales in R&D, reflecting its strategic intent to drive innovation in oncology drug development.
See More
Darovasertib Combination Therapy Significantly Improves Survival Rates
- Clinical Trial Results: At the 2026 ASCO Annual Meeting, IDEAYA presented data showing that the darovasertib and crizotinib combination therapy achieved a median progression-free survival (PFS) of 6.9 months compared to 3.1 months in the control group, indicating its potential as a new therapeutic standard for HLA*A2:01 negative metastatic uveal melanoma.
- Efficacy Metrics Improvement: The combination therapy demonstrated an overall response rate (ORR) of 37.1%, significantly higher than the 5.8% in the control group, suggesting a substantial therapeutic effect that could alter current treatment protocols.
- Good Safety Profile: The safety profile of the combination therapy was consistent with prior results, with treatment-related serious adverse events (TR-SAE) occurring at a rate of 9.2%, lower than the 25.0% in the control group, indicating good tolerability and low discontinuation rates.
- Regulatory Submission Progress: IDEAYA is in the process of submitting a New Drug Application (NDA), expected to be completed in the second half of 2026, which, if approved, will provide new treatment options in this field and further enhance the company's leadership in precision medicine.
See More
IDEAYA Grants 221,000 Stock Options to New Employees
- Stock Option Grant: On May 28, 2026, IDEAYA granted 221,000 non-qualified stock options to six newly hired employees as an inducement for joining the company, in compliance with Nasdaq Listing Rule 5635(c)(4).
- Exercise Price: The stock options have an exercise price of $29.34 per share, which matches the closing price of IDEAYA's common stock on the grant date, aligning employee interests with the company's stock performance.
- Vesting Schedule: The granted stock options have a 10-year term and will vest over four years, with 25% vesting on the first anniversary of the vesting commencement date and the remaining 75% vesting in equal monthly installments over the following three years, ensuring ongoing employee contributions to IDEAYA.
- Company Overview: IDEAYA is a precision medicine oncology company focused on developing transformative therapies for cancer, integrating expertise in small-molecule drug discovery, structural biology, and bioinformatics to advance personalized treatment options.
See More
IDEAYA Enters Clinical Collaboration with Roche for IDE892 Evaluation
- Clinical Collaboration Initiated: IDEAYA has entered into a clinical collaboration with Roche to evaluate its potential best-in-class PRMT5 inhibitor, IDE892, in combination with Roche's RG6505 for MTAP-deleted pancreatic ductal adenocarcinoma patients, demonstrating a strong response to unmet medical needs.
- Trial Design and Implementation: IDEAYA will sponsor the clinical trial while Roche will supply RG6505, with joint governance ensuring scientific rigor and efficacy of the study, thereby advancing the development of new therapies.
- Market Potential Assessment: MTAP deletion occurs in up to 40% of pancreatic ductal adenocarcinoma cases, with nearly all MTAP-deleted cases harboring RAS mutations, indicating that combination therapy may provide new targeted treatment options for these patients, filling a significant market gap.
- Future Development Plans: The collaboration may also evaluate a triplet therapy involving IDE892, RG6505, and IDE397 upon joint approval, further expanding IDEAYA's drug combination strategy for MTAP-deletion, enhancing its competitiveness in the precision medicine field.
See More
IDEAYA Partners with Roche for Clinical Trial of IDE892
- Clinical Collaboration Initiated: IDEAYA has entered into a clinical collaboration with Roche to evaluate the efficacy and safety of its potential best-in-class PRMT5 inhibitor, IDE892, in combination with Roche's RG6505 for pancreatic ductal adenocarcinoma (PDAC), marking a significant advancement in the company's precision medicine strategy.
- Addressing Market Needs: With MTAP deletions occurring in up to 40% of PDAC cases and almost no approved targeted treatment options available, this collaboration aims to fill a critical gap in the market, potentially leading to the development of new therapeutic options for patients.
- Strategic R&D Integration: IDE892 has demonstrated robust monotherapy regressions in preclinical models with MTAP deletions, and the clinical trial combining it with RG6505 will provide crucial data to support IDEAYA's MTAP deletion drug portfolio, enhancing the competitiveness of its pipeline.
- Future Development Potential: The collaboration also allows for the evaluation of a triplet therapy involving IDE892, RG6505, and IDE397, which, if approved, could open new avenues for IDEAYA in precision oncology, significantly boosting its market position.
See More
IDEAYA and Roche Collaborate on New Cancer Therapy Evaluation
- Joint Clinical Trial: IDEAYA Bioscience and Roche have agreed to evaluate a combination therapy of IDE892 and RG6505, targeting pancreatic cancer patients with MTAP deletion, which occurs in up to 40% of cases, indicating potential treatment hope.
- Drug Mechanism Analysis: IDE892, an MTA-cooperative PRMT5 inhibitor, combined with Roche's pan-RAS inhibitor RG6505, may offer deeper and more durable responses for patients currently lacking approved targeted treatment options.
- Trial Sponsorship: IDEAYA will sponsor this clinical trial, further advancing research on RAS-mutant pancreatic cancer with MTAP deletion, aiming to fill treatment gaps and improve patient survival rates.
- Triple Combination Evaluation: The collaboration will also assess a triplet combination of IDE892, RG6505, and IDE397, the latter being IDEAYA's phase 2 MAT2A inhibitor, potentially providing more treatment options for patients.
See More
IDEAYA and Servier Present OptimUM-02 Trial Data for Darovasertib at ASCO 2026
- Clinical Trial Progress: At the 2026 ASCO Annual Meeting, IDEAYA and Servier presented data on the combination of darovasertib and crizotinib for HLA*A2:01 negative metastatic uveal melanoma, demonstrating significant efficacy compared to existing treatments, potentially establishing a new therapeutic standard.
- Patient Recruitment: The OptimUM-02 trial enrolled 313 patients, randomized 2:1 to compare the darovasertib combination with investigator's choice therapy, highlighting the combination's potential in patients with no effective treatment options.
- FDA Review Progress: IDEAYA received FDA agreement in April 2026 to initiate the drug application review for darovasertib, with expectations to complete the filing in the second half of 2026, aiming to expedite the availability of new therapies to meet patient needs.
- Commitment to R&D Investment: Servier achieved €6.9 billion in revenue for the 2024/25 fiscal year and plans to invest nearly 20% of its brand sales in R&D, reflecting its strategic intent to drive innovation in oncology drug development.
See More
Darovasertib Combination Therapy Significantly Improves Survival Rates
- Clinical Trial Results: At the 2026 ASCO Annual Meeting, IDEAYA presented data showing that the darovasertib and crizotinib combination therapy achieved a median progression-free survival (PFS) of 6.9 months compared to 3.1 months in the control group, indicating its potential as a new therapeutic standard for HLA*A2:01 negative metastatic uveal melanoma.
- Efficacy Metrics Improvement: The combination therapy demonstrated an overall response rate (ORR) of 37.1%, significantly higher than the 5.8% in the control group, suggesting a substantial therapeutic effect that could alter current treatment protocols.
- Good Safety Profile: The safety profile of the combination therapy was consistent with prior results, with treatment-related serious adverse events (TR-SAE) occurring at a rate of 9.2%, lower than the 25.0% in the control group, indicating good tolerability and low discontinuation rates.
- Regulatory Submission Progress: IDEAYA is in the process of submitting a New Drug Application (NDA), expected to be completed in the second half of 2026, which, if approved, will provide new treatment options in this field and further enhance the company's leadership in precision medicine.
See More
IDEAYA Grants 221,000 Stock Options to New Employees
- Stock Option Grant: On May 28, 2026, IDEAYA granted 221,000 non-qualified stock options to six newly hired employees as an inducement for joining the company, in compliance with Nasdaq Listing Rule 5635(c)(4).
- Exercise Price: The stock options have an exercise price of $29.34 per share, which matches the closing price of IDEAYA's common stock on the grant date, aligning employee interests with the company's stock performance.
- Vesting Schedule: The granted stock options have a 10-year term and will vest over four years, with 25% vesting on the first anniversary of the vesting commencement date and the remaining 75% vesting in equal monthly installments over the following three years, ensuring ongoing employee contributions to IDEAYA.
- Company Overview: IDEAYA is a precision medicine oncology company focused on developing transformative therapies for cancer, integrating expertise in small-molecule drug discovery, structural biology, and bioinformatics to advance personalized treatment options.
See More
